Mallinckrodt secures FDA approval — but not without warning

The American-Irish pharma said Thursday that the regulatory agency approved its injection terlipressin, now marketed as Terlivaz for patients with hepatorenal syndrome, or HRS. Combined with rapid reduction in liver function, the disease occurs in patients with advanced stages of liver disease and can be life-threatening.